Daniel has recently expanded his technical skill base into SAS programming
and has completed the Philadelphia University SAS training course for the pharmaceutical industry.
He also received his SAS Base certification for SAS 9 and is working at a
local CRO producing and validating analysis datasets, tables, listings, and figures for clinical trial data.
Previously he was engaged in drug discovery efforts
at Cephalon, Inc. in West Chester, Pennsylvania.
While there, he cloned, expressed, and purified
many kinases in support of drug screening,
crystallography studies, and protein/drug
interactions. He also
supported chemistry efforts by assaying compound
degradation in liver microsomes using LC/MS
techniques, as well as p450 gene regulation via
Cephalon, Daniel worked at Boehringer-Ingelheim Pharmaceuticals
in Ridgefield, Connecticut, where he had a
chance to apply his growing skills to research
efforts in HIV. His main focus was to
characterize the genetic changes occurring to HIV
reverse transcriptase in patients undergoing
concomitant drug therapy. After many years of
work, the company announced that the FDA had
approved Viramune (nevirapine), the first
non-nucleoside inhibitor of HIV reverse
transcriptase. The group Daniel was part of
received several company awards for their work.
In 1984, Daniel
met some scientists from Baylor who were going to
establish a new department at the Southwest
Foundation for Biomedical Research. He was
offered an opportunity to join them in starting
the Department of Virology and Immunology under
the directorship of Dr. Gordon Dreesman. With a
new threat from the HIV epidemic, the primate
facility at SFBR would be an important resource. His
duties there would be to utilize computer
programs and immunoassays to predict the immunodominant epitopes
on the envelope glycoprotein of HIV in the hope
of developing a synthetic peptide vaccine. Some
of the results were published in Science in 1986.
his career shortly after receiving his bachelor's
degree in the natural sciences from Indiana
University of Pennsylvania in 1982. The first job
he had was in the laboratory of Dr. James P.
Chambers at the University of Texas Health
Science Center in Houston, Texas. Dr. Chambers'
interest in characterizing various isoforms of
glucosidase allowed Daniel to begin learning how
to apply all that stuff from college to the real
world of scientific research.